AIMS: To provide clinical outcome data from everyday practice for the new generation Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS: Patients were eligible if placement of ≥1 R-ZES was intended. There were no restrictions on clinical indication, number of treated vessels, and lesion characteristics. The primary endpoint was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. Twenty-five per cent of the patients were randomly selected for monitoring. We recruited 2,349 patients with 3,147 lesions (1.6±1.0 stents per patient); 46.0% of patients had acute coronary syndrome, 30.5% were diabetic, and ≥1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was complete in 97.9% of patients. The 1-year incidence of the primary endpoint was 4.3% (95% CI: 3.5% to 5.2%) and for ARC definite and probable stent thrombosis, 0.9% (0.5% to 1.3%). Clinically driven target lesion revascularisation and target lesion failure were 3.4% (2.7% to 4.3%) and 7.0% (6.0% to 8.2%), respectively. These findings were consistent across all lesion and patient subsets analysed. There were no significant differences in outcomes between monitored and unmonitored patients. CONCLUSIONS: In everyday practice, the R-ZES performed similarly well as in the RESOLUTE All Comers randomised trial.
AIMS: To provide clinical outcome data from everyday practice for the new generation Resolute zotarolimus-eluting stent (R-ZES). METHODS AND RESULTS:Patients were eligible if placement of ≥1 R-ZES was intended. There were no restrictions on clinical indication, number of treated vessels, and lesion characteristics. The primary endpoint was the adjudicated cumulative 1-year incidence of cardiac death and target vessel myocardial infarction. Twenty-five per cent of the patients were randomly selected for monitoring. We recruited 2,349 patients with 3,147 lesions (1.6±1.0 stents per patient); 46.0% of patients had acute coronary syndrome, 30.5% were diabetic, and ≥1 complex criterion for stent placement was present in 67.5% of patients. One-year follow-up was complete in 97.9% of patients. The 1-year incidence of the primary endpoint was 4.3% (95% CI: 3.5% to 5.2%) and for ARC definite and probable stent thrombosis, 0.9% (0.5% to 1.3%). Clinically driven target lesion revascularisation and target lesion failure were 3.4% (2.7% to 4.3%) and 7.0% (6.0% to 8.2%), respectively. These findings were consistent across all lesion and patient subsets analysed. There were no significant differences in outcomes between monitored and unmonitored patients. CONCLUSIONS: In everyday practice, the R-ZES performed similarly well as in the RESOLUTE All Comers randomised trial.
Authors: Eric Maupas; Janusz Lipiecki; Raphy Levy; Benjamin Faurie; Bernard Karsenty; Marc Eric Moulichon; François Brunelle; Luc Maillard; Fabien de Poli; Thierry Lefèvre Journal: Catheter Cardiovasc Interv Date: 2017-05-22 Impact factor: 2.692